Table 4.
Risk of prostate cancer death by statin use after ADT stratified by various baseline variables.
| Participants/deaths | Risk of PCA death among ADT treated patients with statin use | |||
|---|---|---|---|---|
| Age-adjusted | Multivariable adjusted | |||
| HR (95% CI) | HR (95% CI)* | |||
| FinRSPC randomization group | Control arm | 2815/547 | 0.70 (0.58–0.84) | 0.80 (0.66–0.98) |
| Screening arm | 1613/287 | 0.64 (0.49–0.84) | 0.63 (0.48–0.83) | |
| Statin use before ADT | No | 2904/593 | 0.58 (0.46–0.73) | 0.67 (0.53–0.84) |
| Yes | 1524/241 | 0.68 (0.51–0.91) | 0.88 (0.66–1.18) | |
| Metastatic PCa at diagnosis | No | 3871/501 | 0.75 (0.62–0.90) | 0.74 (0.61–0.90) |
| Yes | 556/333 | 0.88 (0.66–1.17) | 0.93 (0.69–1.24) | |
| PCa risk group** | Low risk | 768/72 | 0.68 (0.41–1.11) | 0.71 (0.43–1.20) |
| Intermediate risk | 1639/150 | 0.72 (0.51–1.01) | 0.62 (0.44–0.88) | |
| High risk | 2021/612 | 0.77 (0.64–0.92) | 0.78 (0.64–0.94) | |
| Choice of primary treatment | Active surveillance | 390/31 | 0.76 (0.35–1.63) | 0.76 (0.34–1.70) |
| Radical prostatectomy | 332/60 | 0.75 (0.42–1.31) | 0.85 (0.48–1.53) | |
| Radical radiotherapy | 538/90 | 0.74 (0.48–1.16) | 0.74 (0.46–1.18) | |
| Radiation therapy | No | 2172/582 | 0.70 (0.58–0.86) | 0.85 (0.69–1.04) |
| Before ADT | 299/62 | 0.70 (0.41–1.20) | 0.67 (0.38–1.16) | |
| After ADT | 1957/190 | 0.82 (0.61–1.11) | 0.77 (0.57–1.06) | |
| Use of antidiabetic drugs | No | 3463/661 | 0.68 (0.57–0.82) | 0.74 (0.62–0.90) |
| Yes | 965/173 | 0.68 (0.50–0.94) | 0.74 (0.53–1.02) | |
| Socioeconomic status | Employed | 503/119 | 0.79 (0.53–1.18) | 0.88 (0.58–1.34) |
| Unemployed | 111/23 | 0.53 (0.15–1.83) | 0.77 (0.21–2.86) | |
| Retired | 3772/677 | 0.66 (0.56–0.79) | 0.71 (0.60–0.85) | |
| Marital status | Single/divorced/widow | 1244/263 | 0.67 (0.50–0.89) | 0.74 (0.55–1.01) |
| Married/registered partnership | 3184/571 | 0.70 (0.59–0.84) | 0.75 (0.62–0.91) | |
*Calculated using Cox regression with adjustment for age, tumor risk group, randomization group, use of other medication (antidiabetic and antihypertensive drugs, NSAIDs), and whether participants received radiation therapy in addition to ADT.
**Low risk: Gleason <7, T1/2 and PSA below 10, Intermediate risk: Gleason 7, T3 or PSA between 10 and 20, High risk: Gleason >7, T4, M+ or PSA above 20.